Alkermes, Inc v Nektar Therapeutics

Link copied
Case Copied 40 min read

ABSTRACTS OF DECISIONS

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Application  :          No. 760537 in the name of Nektar Therapeutics

Title:          Perforated Microparticles and Methods of Use

Action:          Opposition under section 59 by Alkermes, Inc.

Decision:          Issued  18 December 2007

Abstract

None of the claims are entitled to claim priority from the priority document PD1 and hence documents D4-D6 are all part of the prior art base for the purposes of novelty. Neither D5 nor D6 deprive any of the claims of their novelty.  However, D4 deprives claims 1- 19, 23-39, 42-46, 49, 50, 51 of their novelty as these claims include vaccination.  In contrast, claims 20-22, 40, and 41, 47 and 48, 52 are novel in light of the D4 because this citation does not disclose the claimed microparticles to be suspended in a non-aqueous suspension medium, particles with a mean geometric diameter of 1-30µm and less than 5 µm respectively or an immune response which is enhanced by at least 25%.  

Claims 10-29, 31-34 define microparticles which enhance the effect of immunoactive agents or immunomodulators other than antigens for vaccines. Such claims (as they relate to immunomodulators other than vaccines) are novel in light of D4 which primarily focused on vaccination and did not provide sufficient disclosure to deprive other types of immunomodulation of their novelty.

Only D5 was found to be part of the prior art base for inventive step but the opponent failed to show that the importance of surfactants in improving flowability of the microparticles would have been recognised at the relevant date by the skilled worker.  Hence none of the citations deprived any of the claims of their inventive step. 

PATENTS ACT 1990

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Re:Patent Application No. 760537 in the name of Nektar Therapeutics and an opposition under section 59 by Alkermes, Inc.

BACKGROUND

1.Patent application 760537 (35469/99) now in the name of Nektar Therapeutics was filed on 31 March 1999 under the provisions of the PCT.  It claimed priority from a number of earlier US basic applications:

09/106,932 filed 29 June 1998 (PD-2)
09/133,848 filed on 14 August 1998 (PD-3),
PCT/US98/20603 filed 29 September 1998 (PD-4)
PCT/US98/20602 filed 29 September 1998 (PD-5)
PCT/US98/20615 filed on 29 September 1998 (PD-6)
PCT/US98/20613 filed on 29 September 1998 (PD-7)
09/218,213 filed on 22 December 1998 (PD-8)
09/219,736 filed on 22 December 1998 (PD-9)
09/218,209 filed on 22 December 1998 (PD-10) and
09/218,212 filed on 22 December 1998 (PD-11). 

2.Four of the priority documents were PCT applications (PD4-7) which had equivalent Australian applications (summarised in annex 1).   One of these Australian applications [10644/99 (757337) related to PD-4] claimed priority from an earlier US basic application [60/060337 (PD1)] filed on 29 September 1997.  As this priority did not flow through to the opposed application, the Australian equivalent of PD4 (757337) had an earlier priority date than the current application and was part of the prior art base for novelty for the current application.…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Alkermes, Inc v Nektar Therapeutics and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2007] APO 39
Decision Date

CaseChat Overview and Summary

In the case of Alkermes, Inc v Nektar Therapeutics, the Commissioner of Patents was asked to decide whether patent application number 760537, which related to perforated microparticles and their use, was novel and involved an inventive step. The decision found that none of the priority documents deprived the claims of their novelty, as the opponent had not shown that the priority documents contained sufficient information to deprive the claims of their novelty. The decision also found that none of the claims were entitled to claim priority from the priority document PD1, and hence documents D4-D6 were all part of the prior art base for the purposes of novelty. While D4 deprived claims 1- 19, 23-39, 42-46, 49, 50, 51 of their novelty as these claims included vaccination, claims 20-22, 40, and 41, 47 and 48, 52 were novel in light of the D4 because this citation did not disclose the claimed microparticles to be suspended in a non-aqueous suspension medium, particles with a mean geometric diameter of 1-30µm and less than 5 µm respectively or an immune response which is enhanced by at least 25%. Claims 10-29, 31-34 also encompassed microparticles which enhance the effect of immunoactive agents or immunomodulators other than antigens for vaccination, and such claims were novel in light of D4 which primarily focused on vaccination and did not provide sufficient disclosure to deprive other types of immunomodulation of their novelty. The opponent failed to show that the importance of surfactants in improving flowability of the microparticles would have been recognised at the relevant date by the skilled worker, and hence none of the citations deprived any of the claims of their inventive step. The decision concluded that the application contained patentable subject matter and allowed the applicant 60 days in which to propose amendments to overcome the deficiencies noted in this decision.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.